- Report
- December 2022
- 260 Pages
Global
From €2127EUR$2,400USD£1,825GBP
- Report
- April 2024
- 115 Pages
United States
From €1595EUR$1,800USD£1,369GBP
- Report
- October 2023
- 377 Pages
Global
From €3722EUR$4,200USD£3,194GBP
- Report
- January 2025
- 150 Pages
Global
From €4121EUR$4,650USD£3,536GBP
- Report
- January 2025
- 159 Pages
Global
From €4121EUR$4,650USD£3,536GBP
- Report
- April 2024
- 121 Pages
Global
From €4121EUR$4,650USD£3,536GBP
- Report
- July 2023
- 152 Pages
Global
From €4121EUR$4,650USD£3,536GBP
- Report
- June 2023
- 186 Pages
Global
From €4121EUR$4,650USD£3,536GBP
- Report
- February 2022
- 157 Pages
Global
From €4874EUR$5,500USD£4,182GBP
- Report
- March 2021
- 345 Pages
Global
From €2437EUR$2,750USD£2,091GBP
- Report
- August 2025
- 200 Pages
United States
From €2207EUR$2,490USD£1,893GBP
- Report
- March 2025
- 200 Pages
Japan
From €2207EUR$2,490USD£1,893GBP
- Report
- May 2024
- 100 Pages
China
From €2029EUR$2,290USD£1,741GBP
- Report
- February 2023
- 150 Pages
United States
From €2207EUR$2,490USD£1,893GBP
- Report
- February 2025
- 316 Pages
Global
From €3988EUR$4,500USD£3,422GBP
- Report
- March 2025
- 140 Pages
Global
From €4342EUR$4,900USD£3,726GBP
- Report
- April 2025
Global
From €4342EUR$4,900USD£3,726GBP
- Report
- February 2025
- 68 Pages
Asia Pacific
From €2880EUR$3,250USD£2,471GBP
- Report
- February 2025
- 71 Pages
Europe
From €2880EUR$3,250USD£2,471GBP
- Report
- November 2024
- 73 Pages
Asia Pacific
From €2880EUR$3,250USD£2,471GBP

The Liquid Biopsy market within the Pharmaceuticals industry is a rapidly growing field of research and development. It is a minimally invasive procedure that uses a sample of blood to detect and monitor cancer. It is used to detect cancer at an early stage, to monitor the progression of the disease, and to assess the effectiveness of treatments. Liquid biopsy can also be used to detect genetic mutations associated with cancer, which can help guide treatment decisions.
The Liquid Biopsy market is expected to grow significantly in the coming years due to its potential to improve patient outcomes and reduce healthcare costs. It is also expected to benefit from advances in technology, such as the development of more sensitive and specific tests.
Some companies in the Liquid Biopsy market include Guardant Health, Exact Sciences, Biocept, and Genomic Health. Show Less Read more